02524cab a2200301Ia 4500001000800000003000600008008004100014040000800055041001300063100002300076240008400099245019400183246026900377300001400646504002500660520115800685546002301843650002401866650002001890650002101910650004201931650001401973700002101987700002202008700002902030773008602059856007702145u210887SIRSI110402s2014    ua     ss b         eng d  aEAL  aengbara1 aAbd El Aziz, M. I.10akafrelsheikh veterinary medical journal, 2014 v. 12 (1)h[electronic resource].14aThe effect of tilmicosin and apramycin alone or together in treatment of experimentally infected chickens with Mycoplasma Gallisepticum only or with Escherichia colih[electronic resource].15aتأثير كل من التلميكوزين والأبراميسن منفردين أو مجتمعين في علاج الدجاج المعدي معملياً الميكوبلازما جاليسبتكم منفردة أو مع الايشريشيا كولاي.  ap.139-178  aIncludes references.  aMycoplasmosis remains one of the most expensive and common diseases facing poultry industry. The presence of Mycoplasma gallisepticum (MG) predisposes birds to other infections as Escherichia coli which together causes mortality, and sub-optimal performance. Therefore, this study was carried out to evaluate the efficacy of tilmicosin, apramycin and both drugs together on experimentally infected chicken with local field isolates of MG only or with E. coli as CRD and CCRD treatments. The present investigation clarified that infected groups treated with both tilmicosin and apramycin showed additive or synergistic interaction between them, which in turn confirmed the safoty use of this combination therapy. The use of the recommended therapeutic dose oftilmicosin (lml/L) or apramycin (0.5gm/L) alone or in combination for 5 successive days after appearance of the clinical signs are of considerable value in the treatment of MG injection in broiler chickens as antimycoplasmal drugs through displayed valuable improvement in clinical symptoms, survival rate, lesion scoring and termination of infection by the mycoplasmacidal effect of both drugs.  aSummary in Arabic. 0aChickensxDiseases. 0aMycoplasmatales 0aEscherichia coli 0aAntibacterial agentsxtherapeutic use 3aapramycin1 aEl Shazly, K. A.1 aEl Kahky, Mona A.1 aEl Sherbeneyn, Ema M. E.0 tKafrelsheikh Veterinary Medical Journal. g2014.v.12(1)x1687-14567nnaswu19077340uhttp://nile.enal.sci.eg/EALE/2014/KVMJ/1214/1/139.pdfzFull Text Article